Using a Revenue DCF model with operating margin convergence from -101.2% to a target of 13.3% over 5 years, discounted at a WACC of 8.7%, Rhythm Pharmaceuticals, Inc. (RYTM) has an intrinsic value of $60.38 per share (range: $3.19 – $207.22).
Using a Revenue DCF model with operating margin convergence from -101.2% to a target of 13.3% over 5 years, discounted at a WACC of 8.7%, Rhythm Pharmaceuticals, Inc. (RYTM) has an intrinsic value of $16.06 per share (range: $1.40 – $67.03).
Using the industry peer median EV/Revenue multiple (trailing + forward), Rhythm Pharmaceuticals, Inc. (RYTM) has a fair value of $45.88 based on 7 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Rhythm Pharmaceuticals, Inc.RYTM | 5,679 | 30.9x | 19.7x |
| Protagonist Therapeutics, Inc. | 6,565 | 140.1x | 14.6x |
| Kiniksa Pharmaceuticals, Ltd. | 3,677 | 5.2x | 3.9x |
| Relay Therapeutics, Inc. | 2,225 | 141.6x | — |
| Syndax Pharmaceuticals, Inc. | 2,142 | 13.7x | 6.5x |
| Stoke Therapeutics, Inc. | 1,940 | 10.1x | 10.1x |
| Viridian Therapeutics, Inc. | 1,179 | 14.4x | 14.2x |
| uniQure N.V. | 1,071 | 94.9x | 47.2x |
| Industry Median | 14.4x | 12.2x | |
| (*) Revenue | 190 | 298 | |
| = Enterprise Value | 2,726 | 3,621 | |
| (-) Net Debt | 192 | 192 | |
| Equity Value | 2,534 | 3,429 | |
| (/) Outstanding shares | 65 | 65 | |
| Fair Price | $39 | $53 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.